权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A comprehensive quality control testing strategy for engineered cells

工程细胞的全面质量控制测试策略

基本信息

批准号：
10330008
负责人：
Christopher John Tompkins
金额：
$ 35.05万
依托单位：
KROMATID, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-15 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10330008
关键词：
Address Alleles Aneuploidy Bioinformatics Biological Assay Biomedical Research CRISPR/Cas technology Cell Therapy Cells Chromatids Chromosomes Clinical Clinical Engineering Collaborations Collection Color Complex Contracts DNA Repair Data Data Set Defect Detection Development Disease Double Strand Break Repair Engineering Exhibits Funding G-Banding Genes Genome Genome engineering Genomic Hybridizations Genomics Goals Government Health Hereditary Disease Human In Situ Hybridization Individual Inherited Karyotype Karyotype determination procedure Knowledge Malignant Neoplasms Measurement Measures Medical Methods Modeling Monitor Nucleotides Outcome Paint Patients Pediatric Hospitals Pharmacologic Substance Polyploidy Population Process Provider Quality Control Research Resolution Risk Safety Saint Jude Children&apos s Research Hospital Sampling Sister Chromatid Exchange Site Source Speed Structure System Techniques Technology Testing Therapeutic Time Training Variant Work Writing base cellular engineering clinical application commercial application comparative data standards density design experience experimental study fluorophore gene therapy genome editing genome integrity genomic data high resolution imaging improved innovation insertion/deletion mutation patient safety predictive modeling programs reference genome research and development screening stem cells technological innovation therapeutic gene therapy development tool whole genome

项目摘要

ABSTRACT KromaTiD’s current commercial therapeutic gene editing customers have expressed the critical need for a standard approach to screening engineered cells for quality and safety that yields a comprehensive genomic dataset with improved resolution, localization, and speed. Directional Genomic Hybridization (dGH™) has been developed to efficiently screen cell populations for the presence of simple, complex, and heterogenous structural variants. In this project, A Comprehensive Quality Control Testing Strategy for Engineered Cells, by combining five-color, whole genome dGH with the fit for purpose sequencing methods of a clinically important genome engineering system, we propose an approach to assess, for the first time, the complete outcomes of gene editing: successful edits, unsuccessful edits, off-target edits, sequence variants, structural variants, and gross genome integrity. Furthermore, we propose to develop a standardized data specification integrating the data from these methods into a regulatory ready data package. dGH is an in-situ hybridization technique utilizes high-density chromatid paints to directly interrogate the structure of a genome in a single cell without bioinformatic interpretation, providing a complete toolset for hypothesis-free, single-cell measurement of SVs at edit sites, per chromosome, and across the whole genome. For companies developing therapies based on gene editing and other cell engineering approaches, understanding editing systems and mis-repair of DSBs are critical for patient safety and regulatory approval. Currently, batches of edited cells are screened for edit-site errors by sequencing. Because DSBs do not all occur at the edit site, SVs in batches of edited cells exhibit a complex, heterogenous mixture of edit-site and random breakpoints. G-banding can be used to screen for gross genome defects but cannot detect small or complex structural variants. dGH assays detect structural variation from a reference genome without target information, resolve SVs of 5Kb and larger, and provide improved genomic structural assessment capable of displacing standard karyotyping. The potential of genome editing approaches such as CRISPR/Cas9, for the treatment of diseases is widely recognized, and realization of the promise of such therapeutic approaches will rely on accurate confirmation of the presence and absence of potentially risky structural variants. For these reasons, comprehensive detection and characterization of structural variations is a necessary step toward understanding gene editing and other cell engineering systems. dGH combined with best-fit sequencing can provide a complete analysis of the outcomes of gene editing from SNVs and indels though large, complex SVs.

摘要